XNK: XNK partners with Swedish hospital to develop AML therapy
XNK Therapeutics adds another research partner to evaluate XNK's natural killer cell therapy candidate in acute myeloid leukaemia.
Read full article »
XNK is a Switzerland-based clinical-stage biotechnology company that researches and develops novel NK cell-based therapies for the treatment of cancer.
Read more